Poland· PL-100390624
Kevzara
A sarilumab product containing sarilumabum, registered in Poland by Sanofi Winthrop Industrie. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Sarilumab is registered in 13 of 19 countries.
Countries holding a registration under ATC L04AC14 (sarilumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Sarilumab · ATC L04AC14
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of sarilumab costs, country by country.
Normalised to the WHO defined daily dose (14.3 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Sarilumab · price per daily dose (14.3 mg)
USD · FX 28 Sept 2026
- CH Switzerland$60.91
The record
At a glance
URPL (Poland)- Active substance
- Sarilumabum
- Manufacturer
- Sanofi Winthrop Industrie
- Country
- Poland (PL)
- ATC code
- L04AC14
- ATC class
- Sarilumab
- Defined daily dose
- 14.3 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 3
- gtin05909991336301
- gtin05909991336318
- gtin05909991358297
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
190 interactions on record for sarilumab.
Graded by severity as the source publishes them — 39 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Sarilumab · interactions on record
190 records
- 39 severe
- 144 moderate
- 7 minor
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- CladribineL01BB04severe
- PexidartinibL01EX15severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Sarilumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaKEVZARASanofi Winthrop Industrie, Gentilly
- BelgiumKevzara 200 mgSanofi Winthrop Industrie
- SpainKEVZARA 200 MG SOLUCION INYECTABLE EN JERINGA PRECARGADASanofi Winthrop Industrie
- IcelandKevzaraSanofi Winthrop Industrie
- SwedenKevzara 200 mg Injektionsvätska, lösning i förfylld injektionspennaSanofi Winthrop Industrie
- FinlandKevzaraSanofi Winthrop Industrie
- NetherlandsKevzara 150 mg, oplossing voor injectie in voorgevulde penSanofi Winthrop Industrie
- United StatesKEVZARASanofi-Aventis U.S. LLC
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Kevzara
- Liechtenstein · Kevzara
- Norway · Kevzara
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/40ae41cd-9b44-4d86-af68-e696852cb17b GET /v1/drugs/40ae41cd-9b44-4d86-af68-e696852cb17b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań we wstrzykiwaczu",
"source": "urpl",
"strength": "200 mg",
"packaging": "05909991336301 ¦ Rpz ¦ EU/1/17/1196/007 ¦ 123298\n2 wstrzykiwacze 1,14 ml\n05909991336318 ¦ Rpz ¦ EU/1/1 7/1196/008 ¦ 123299\n6 wstrzykiwaczy 1,14 ml\n05909991358297 ¦ Rpz ¦ EU/1/17/1196/012 ¦ 125461\n1 wstrzykiwacz 1,14 ml",
"substance": "Sarilumabum 175 mg/ml",
"common_name": "Sarilumabum",
"pl_product_id": "100390624",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about sarilumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.